drugset / Trial / NCT05571267
Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective is to assess the safety of intravitreal (IVT) Zimura® administered in combination with anti-VEGF Therapy (AVASTIN®, EYLEA®, OR LUCENTIS®) in anti-VEGF treatment experienced subjects with neovascular age-related macular degeneration (AMD)
Timeline
- Start
- 2016-10-20
- Primary completion
- 2018-04-24
- Completion
- 2018-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | Avacincaptad Pegol | Aptamer | 2 mg | Intravitreal |
| Subject | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |